Epigallocatechin-3-<i>O</i>-gallate alleviates the malignant phenotype in A-431 epidermoid and SK-BR-3 breast cancer cell lines

Filippi, Alexandru; Picot, Tiphanie; Aanei, Carmen Mariana; Nagy, Péter; Szöllősi, János; Campos, Lydia; Ganea, Constanţa; Mocanu, Maria-Magdalena

doi:10.1080/09637486.2017.1401980

Cited by 12 publications

(9 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EGCG is able to stop growth of MCF-7Tam cells, a breast carcinoma cell line resistant to tamoxifen, through downregulation of EGFR, EMMPRIM and other molecules implicated in an aggressive biological behavior [31]. This catechin inhibits EGFR signaling pathway, mainly by direct inhibition of ERK1/2 and Akt kinases, which supports the role of EGCG as an inhibitor of breast cancer cell proliferation since this pathway is intrinsically related to the control of cell proliferation [32].…”

Section: Induction Of Cell Cycle Arrest (Table 2)mentioning

confidence: 55%

“…Similarly, Hong et al proved that EGCG decreases MDA-MB-231 cell viability through downregulation of the expression of β-catenin, cyclin D1, and p-AKT [39]. Moreover, Filippi et al demonstrated that EGCG was able to reduce the viability of SK-BR-3 cells, a human breast cancer cell line that overexpresses the Her2 (Neu/ErbB-2) gene product [32]. Finally, EGCG was found to be the most effective inhibitor of MCF-7 cell proliferation and viability, as compared to other epicatechin derivatives such as (-)epicatechin (EC), (-)-epicatechin gallate (ECG), (-)epigallocatechin (EGC) [24].…”

Section: Induction Of Cell Cycle Arrest (Table 2)mentioning

confidence: 98%

See 1 more Smart Citation

The Role of EGCG in Breast Cancer Prevention and Therapy.

Romano

Martel

2021

MRMC

View full text Add to dashboard Cite

Background: Breast cancer is the most frequent cancer in women. Green tea has been studied for breast cancer chemopreventive and possibly chemotherapeutic effects due to its high content in polyphenolic compounds, including epigallocatechin-3-gallate (EGCG). Method: This review is based on a literature research that included papers registered on the Medline database. The research was conducted through PubMed, with the application of the following query: “EGCG”AND "breast cancer”. The result was a total of 88 articles in which this review stands on. Results: In vitro, EGCG shows antioxidant or pro-oxidant properties, depending on the concentration and exposure time. EGCG blocks cell cycle progression and modulates signaling pathways that affects cell proliferation and differentiation. EGCG also induces apoptosis, negatively modulates different steps involved in metastasis and targets angiogenesis by inhibiting VEGF transcription. In vivo, investigations have shown that oral administration of EGCG results in reduction of tumor growth and in antimetastatic and antiangiogenic effects in animal xenograft and allograft models. Discussion: Much remains unknown about the molecular mechanisms involved in the protective effects of EGCG on mammary carcinogenesis. In addition, more studies in vivo are necessary to determine the potential toxicity of EGCG at higher doses and to elucidate its interactions with other drugs. Conclusion: A protective effect of EGCG has been shown in different experimental models and under different experimental conditions, suggesting clinical implications of EGCG for breast cancer prevention and therapy. The data presented in this review support the importance of further investigations.

show abstract

Section: Induction Of Cell Cycle Arrest (Table 2)mentioning

confidence: 55%

Section: Induction Of Cell Cycle Arrest (Table 2)mentioning

confidence: 98%

The Role of EGCG in Breast Cancer Prevention and Therapy.

Romano

Martel

2021

MRMC

View full text Add to dashboard Cite

show abstract

“…Lipid rafts are rich in tyrosine kinase receptors (RTKs), such as EGFR [116,117,118], IGF1R [119], and HER2 [120]. These receptors have been found to be inhibited by EGCG in several in vitro and in vivo cancer models (e.g., colon, lung, liver and breast cancers) [92,121,122,123]. The functional proteins recruited by lipid rafts allow these structures to play complex roles.…”

Section: 67-kda Laminin Receptor Signalling Pathwaysmentioning

confidence: 99%

Molecular Targets of Epigallocatechin—Gallate (EGCG): A Special Focus on Signal Transduction and Cancer

et al. 2018

View full text Add to dashboard Cite

Green tea is a beverage that is widely consumed worldwide and is believed to exert effects on different diseases, including cancer. The major components of green tea are catechins, a family of polyphenols. Among them, epigallocatechin-gallate (EGCG) is the most abundant and biologically active. EGCG is widely studied for its anti-cancer properties. However, the cellular and molecular mechanisms explaining its action have not been completely understood, yet. EGCG is effective in vivo at micromolar concentrations, suggesting that its action is mediated by interaction with specific targets that are involved in the regulation of crucial steps of cell proliferation, survival, and metastatic spread. Recently, several proteins have been identified as EGCG direct interactors. Among them, the trans-membrane receptor 67LR has been identified as a high affinity EGCG receptor. 67LR is a master regulator of many pathways affecting cell proliferation or apoptosis, also regulating cancer stem cells (CSCs) activity. EGCG was also found to be interacting directly with Pin1, TGFR-II, and metalloproteinases (MMPs) (mainly MMP2 and MMP9), which respectively regulate EGCG-dependent inhibition of NF-kB, epithelial-mesenchimal transaction (EMT) and cellular invasion. EGCG interacts with DNA methyltransferases (DNMTs) and histone deacetylases (HDACs), which modulates epigenetic changes. The bulk of this novel knowledge provides information about the mechanisms of action of EGCG and may explain its onco-suppressive function. The identification of crucial signalling pathways that are related to cancer onset and progression whose master regulators interacts with EGCG may disclose intriguing pharmacological targets, and eventually lead to novel combined treatments in which EGCG acts synergistically with known drugs.

show abstract

“…As reported, under some external causes, cells will suffer from serious depletion of mitochondrial membrane potential, thus inducing apoptosis [ 27 ]. The cells treated with 50 µM EGCG for 0.5–24 hours in human glioblastoma cells [ 28 ], or 50–100 µM EGCG for 72 hours in epidermoid carcinoma and breast adenocarcinoma cells both observed a decrease in mitochondrial membrane potential [ 29 ]. Our results also confirmed that EGCG can reduce MMP and induce depolarization through a mitochondrial-dependent pathway, leading to increased apoptosis (Figures 1 and 2 ).…”

Section: Discussionmentioning

confidence: 99%

EGCG Enhances the Chemosensitivity of Colorectal Cancer to Irinotecan through GRP78-MediatedEndoplasmic Reticulum Stress

Gou

Xiang

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

This study aimed to explore the role of GRP78-mediated endoplasmic reticulum stress (ERS) in the synergistic inhibition of colorectal cancer by epigallocatechin-3-gallate (EGCG) and irinotecan (IRI). Findings showed that EGCG alone or in combination with irinotecan can significantly promote intracellular GRP78 protein expression, reduce mitochondrial membrane potential and intracellular ROS in RKO and HCT 116 cells, and induce cell apoptosis. In addition, glucose regulatory protein 78 kDa (GRP78) is significantly over-expressed in both colorectal cancer (CRC) tumor specimens and mouse xenografts. The inhibition of GRP78 by small interfering RNA led to the decrease of the sensitivity of CRC cells to the drug combination, while the overexpression of it by plasmid significantly increased the apoptosis of cells after the drug combination. The experimental results in the mouse xenografts model showed that the combination of EGCG and irinotecan could inhibit the growth of subcutaneous tumors of HCT116 cells better than the two drugs alone. EGCG can induce GRP78-mediated endoplasmic reticulum stress and enhance the chemo-sensitivity of colorectal cancer cells when coadministered with irinotecan.

show abstract

Epigallocatechin-3-O-gallate alleviates the malignant phenotype in A-431 epidermoid and SK-BR-3 breast cancer cell lines

Cited by 12 publications

References 39 publications

The Role of EGCG in Breast Cancer Prevention and Therapy.

The Role of EGCG in Breast Cancer Prevention and Therapy.

Molecular Targets of Epigallocatechin—Gallate (EGCG): A Special Focus on Signal Transduction and Cancer

EGCG Enhances the Chemosensitivity of Colorectal Cancer to Irinotecan through GRP78-MediatedEndoplasmic Reticulum Stress

Contact Info

Product

Resources

About